基因编辑权威指南。
菜单
首页 学习 新闻 向 Atlas 提问
探索 技术 疾病 治疗方法 临床试验 企业 科学家 基因 研究 机构
医学之外 农业 伦理 投资 世界地图
学习与工具 从这里开始 术语表 A–Z 对比技术 时间线 列表与排名 AI 智能体 ★ 已保存 API
关于 关于我们 方法论 数据来源 编辑方针 联系我们 免责声明

🧭 引导视图
遗传学新手?浏览时我们会用简单易懂的语言为您解释每个术语,就在同一页面内,帮助随时可用。

⚡ 专家观点
你已经了解生物学基础,只需内容本身——简洁明了,无额外解释。这是默认视图。

界面语言
浅色模式

临床试验 · Chronic granulomatous disease

The first prime-editing therapy in humans

官方名称: A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease

Recruiting Phase I/II NCT06559176
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

本试验正在测试什么

The first trial to use prime editing in people. Patients' own blood stem cells were corrected outside the body and returned. Both participants reported so far engrafted quickly and regained the immune function they had been missing, with early clinical improvement.

A Phase 1/2 study of PM359, an autologous prime-edited CD34+ cell therapy correcting the NCF1 delGT mutation. Published results in the first two participants, following busulfan conditioning, reported prompt neutrophil and platelet engraftment, 69 and 83 per cent dihydrorhodamine-positive neutrophils by day 30, and durable restoration of NADPH oxidase activity with early clinical benefit.

Sources

试验结果意味着什么,又不意味着什么 早期试验结果来自少量参与者和较短的随访周期,随着人数增加和时间延长,结论可能发生变化。正在招募、进行中甚至已完成的试验,并不代表某种疗法已被证实有效。入组标准十分严格,是否符合条件由试验机构决定,而非由网站判断。

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

Prime Editing

Treatments

PM359

Genes

NCF1

Companies

Prime Medicine